基于药物基因组学的处方实用建议：2010 年 ESF-UB 药物遗传学和药物基因组学会议。

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.

机构信息

Univ Paris-Sud, Faculty of Medicine Paris-Sud, Pharmacology Department, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, France.

出版信息

Pharmacogenomics. 2011 Jan;12(1):113-24. doi: 10.2217/pgs.10.147.

DOI:10.2217/pgs.10.147

PMID:21174626

Abstract

The present article summarizes the discussions of the 3rd European Science Foundation-University of Barcelona (ESF-UB) Conference in Biomedicine on Pharmacogenetics and Pharmacogenomics, which was held in June 2010 in Spain. It was focused on practical applications in routine medical practice. We provide practical recommendations for ten different clinical situations, that have either been approved or not approved by regulatory agencies. We propose some comments that might accompany the results of these tests, indicating the best drug and doses to be prescribed. The discussed examples include KRAS, cetuximab, panitumumab, EGFR-gefitinib, CYP2D6-tamoxifen, TPMT-azathioprine-6-mercaptopurine, VKORC1/CYP2C9-warfarin, CYP2C19-clopidogrel, HLA-B5701-abacavir, HLA-B5701-flucloxacillin, SLCO1B1-statins and CYP3A5-tacrolimus. We hope that these practical recommendations will help physicians, biologists, scientists and other healthcare professionals to prescribe, perform and interpret these genetic tests.

摘要

本文总结了 2010 年 6 月在西班牙举行的第三届欧洲科学基金会-巴塞罗那大学（ESF-UB）会议在药物遗传学和药物基因组学方面的讨论。会议重点是药物遗传学和药物基因组学在常规医疗实践中的实际应用。我们针对十种不同的临床情况提供了实用建议，这些建议或已被监管机构批准，或未被批准。我们提出了一些可能伴随这些测试结果的意见，指出应开出的最佳药物和剂量。讨论的例子包括 KRAS、西妥昔单抗、帕尼单抗、EGFR-吉非替尼、CYP2D6-他莫昔芬、TPMT-巯嘌呤、VKORC1/CYP2C9-华法林、CYP2C19-氯吡格雷、HLA-B5701-阿巴卡韦、HLA-B5701-氟氯西林、SLCO1B1-他汀类药物和 CYP3A5-他克莫司。我们希望这些实用建议能帮助医生、生物学家、科学家和其他医疗保健专业人员开具、执行和解释这些基因测试。